A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer
Phase of Trial: Phase III
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Apatinib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms ANGEL
- Sponsors LSK Biopharma
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 13 Mar 2017 According to a LSK Biopharma media release, first patient has been enrolled in this trial at ASAN Medical Center (AMC) in Seoul, South Korea.
- 06 Mar 2017 Status changed from not yet recruiting to recruiting.